Alnylam Pharmaceuticals, INC. (ALNY) SEC Filings — 2025

Filings

• Alnylam Pharmaceuticals Files 8-K — 8-K · Dec 11, 2025
• Alnylam Pharmaceuticals, INC. 8-K Filing — 8-K · Dec 3, 2025
• Alnylam Swings to Profit on Soaring Product & Collaboration Revenue — 10-Q · Oct 30, 2025
• Alnylam Pharmaceuticals Enters Material Definitive Agreement — 8-K · Oct 3, 2025
• Alnylam Pharmaceuticals Reports Material Agreement and Equity Sales — 8-K · Sep 12, 2025
• Alnylam Pharmaceuticals Files 8-K Report — 8-K · Sep 10, 2025
• Alnylam's Q2 Revenue Soars 60% on Strong Product & Collaboration Growth — 10-Q · Jul 31, 2025
• Alnylam Pharmaceuticals Appoints New Chief Medical Officer — 8-K · Jun 18, 2025
• Alnylam Pharmaceuticals Files 8-K on Governance Matters — 8-K · May 13, 2025
• Alnylam Pharmaceuticals Q1 2025 Update — 10-Q · May 1, 2025
• Alnylam Pharmaceuticals Files Proxy Statement Amendment — DEFA14A · Apr 4, 2025
• Alnylam Pharmaceuticals Files Proxy Materials — DEFA14A · Mar 24, 2025
• Alnylam Pharma Files 2025 Proxy: Executive Equity Awards Detailed — DEF 14A · Mar 24, 2025
• Alnylam Pharmaceuticals Files 8-K Report — 8-K · Mar 21, 2025
• Alnylam Pharmaceuticals Appoints New Directors, Adjusts Executive Pay — 8-K · Mar 5, 2025
• Alnylam Pharmaceuticals Files 2024 10-K — 10-K · Feb 13, 2025
• Alnylam Pharmaceuticals Reports Financial Condition — 8-K · Jan 13, 2025